TB

The World Health Organization’s campaign website for World TB Day. Please check the site frequently, as the webpage may be updated throughout the month.

This webinar was developed for healthcare professionals who care for persons diagnosed with TB infection or disease. The webinar includes a case study regarding diagnostic delays, presented by a speaker from Hidalgo County Health & Human Services. 

The Heartland National TB Center created this factsheet based on the research conducted to develop the presentation for the webinar COVID-19/TB – Diagnostic Delays and Unrecognized Risk for Progression of LTBI to TB Disease. The webinar was developed in partnership between Heartland National TB Center  and the National TB Nurse’s Coalition.

This 90-minute webinar was held for clinicians and others who provide services to TB patients or persons at risk for TB with significant alcohol and/or tobacco use.

This two-hour webinar was developed for clinicians in the United States who may treat or screen patients with tuberculosis, diabetes, or both diseases. The webinar includes a 90-minute presentation and a 30-minute question and answer session.

This 120-minute training was held for clinicians and others who are involved in the diagnosis of active TB. There are three presentations and a question and answer session.

This 90-minute webinar is the first of two webinars to highlight the NTCA/APHL Consensus Statement on the Use of Cepheid GeneXpert MTB/RIF Assay. The second webinar is GeneXpert: Examples From the Field.

This 90-minute webinar is the first of two webinars to highlight the NTCA/APHL Consensus Statement on the Use of Cepheid GeneXpert MTB/RIF Assay. The second webinar is GeneXpert: Examples From the Field.

This 90-minute webinar is the second of two webinars to highlight the NTCA/APHL Consensus Statement on the Use of Cepheid GeneXpert MTB/RIF Assay. The first webinar is Changing TB Isolation Practices: New Guidelines for Molecular Testing.

This 75-minute webinar provides information on how to put together results from conventional growth-based and molecular methods of TB drug susceptibility testing (including conflicting or contradictory results) to request further testing and/or design optimal treatment regimens for TB patients.